[논문]제한된 평균 생존시간을 이용한 위암 3기 자료 분석에 관한 연구

김빛나; 이민정

doi:10.5351/kjas.2021.34.2.255

제한된 평균 생존시간을 이용한 위암 3기 자료 분석에 관한 연구
Analysis of stage III stomach cancer using the restricted mean survival time 원문보기

응용통계연구 = The Korean journal of applied statistics, v.34 no.2, 2021년, pp.255 - 266

초록
AI-Helper

본 연구는 미국 국립암연구소의 SEER 프로그램에서 제공하는 위암 3기 자료에 대해 항암치료의 효과를 비교하고 위암 생존율에 유의한 영향을 미치는 요인을 알아보고자 한다. 본 연구에서 분석한 위암 3기 자료는 비례위험 가정이 성립하지 않아 대안으로 제한된 평균 생존시간을 이용한 분석 방법을 자료 분석에 적용하였다. 의사-관측들을 이용하여 제한된 평균 생존시간을 추정하였고, 제한된 평균 생존시간 추정량에 기반한 검정통계량을 이용하여 항암치료의 효과를 파악하였다. 일반화 선형모형을 이용한 회귀모형을 통해 위암 3기 환자의 평균 생존시간에 유의한 영향을 미치는 공변량들의 효과를 추정하였다. 항암치료법에 따라 위암 3기 환자의 평균 생존시간에 유의한 차이가 있음을 확인하였고, 진단연령, 인종, 세분화병기, 분화도, 종양의 크기, 수술여부, 항암치료가 위암 3기 환자의 평균 생존시간에 유의한 영향을 미치는 요인들이였으며, 그 중 수술여부가 위암 3기 환자의 평균 생존시간을 늘리는데 가장 큰 영향을 미치는 요인임을 확인하였다.

Abstract ▼ AI-Helper

The purpose of this study is to compare the effects of treatment on stage III stomach cancer data obtained from the SEER program of the National Cancer Institute and to identify the significant risk factors for the survival rates of stage III stomach cancer. Since the proportional hazards assumption was violated for treatment, we used the restricted mean survival time as an alternative to the proportional hazards model. The restricted mean survival time was estimated using pseudo-observations, and the effects of treatment were compared using a test statistic based on the estimated restricted mean survival times. We conducted the regression analysis using a generalized linear model to investigate the significant predictors for the restricted mean survival time of patients with stage III stomach cancer. We found that there was a significant difference between the restricted mean survival times of treatment groups. Age at diagnosis, race, substage, grade, tumor size, surgery, and treatment were significant predictors for the restricted mean survival time of patients with stage III stomach cancer. Surgery was the most significant predictor for increasing the restricted mean survival time of patients with stage III stomach cancer.

주제어

표/그림 (8)

표 Table 1: Data characteristics
표 Table 2: The mean and standard deviation of age and tumor size
그림 Figure 1: Estimated survival probabilities for treatment.
표 Table 3: Regression parameter estimates, standard errors, and p-values for death from stomach cancer under the proportional hazards model, and test of the proportional hazards (PH) assumption
표 Table 4: The estimated restricted mean survival times on each group, test statistics comparing the restricted mean survival times of four groups, and p-values when τ = 20, 57, 100, 134 (months)
그림 Figure 2: Schoenfeld residual plots for age, surgery, and treatment, and log[− log{Ŝ(t)}] plot for treatment.
표 Table 5: Regression parameter estimates, standard errors, and p-values for death from stomach cancer under the restricted mean survival time model with the log link function when τ = 20, 57, 100, 134 (months)
표 Table 6: Regression parameter estimates, standard errors, and p-values for death from stomach cancer under the accelerated failure time model

참고문헌 (20)

Andersen PK, Hansen MG, and Klein JP (2004). Regression analysis of restricted mean survival time based on pseudo-observations, Lifetime Data Analysis, 10, 335-350.

상세보기
Andersen PK and Perme MP (2010). Pseudo-observations in survival analysis, Statistical Methods in Medical Research, 19, 71-99.

상세보기
Chen PY and Tsiatis AA (2001). Causal inference on the difference of the restricted mean lifetime between two groups, Biometrics, 57, 1030-1038.

상세보기
Cox DR (1972). Regression models and life-tables (with discussion), Journal of Royal Statistical Society, Series A, 34, 187-220.
Grambsch P and Therneau T (1994). Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81 ,515-526.

상세보기
Guo C and Liang Y (2019). Analyzing restricted mean survival time using SAS/STAT, SAS Institute Inc., Cary, NC.
Irwin JO (1949). The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice, The Journal of Hygiene, 47, 188-189.

상세보기
Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations, Journal of the American Statistical Association, 53, 457-481.

상세보기
Korea Central Cancer Registry (2019). National cancer center, Annual report of cancer statistics in Korea in 2017, Ministry of health and welfare.
Liang KY and Zeger SL (1986). Longitudinal data analysis using generalized linear models, Biometrika, 73, 13-22.

상세보기
National Cancer Information Center (2019). Cancer information service. from: https://www.cancer.go.kr/
Nemes S, Bulow E, and Gustavsson A (2020). A brief overview of restricted mean survival time estimators and associated variances, MDPI Stats, 3, 107-119.
Prentice RL (1978). Linear rank tests with right censored data, Biometrike, 65, 167-180.
Royston P and Parmar MK (2011). The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Statistics in Medicine, 30, 2409-2421.

상세보기
Ruhl J, Ward E, Hofferkamp J, et al (2019). Grade Manual. NAACCR, Springfield, IL 62704-4194.
Schoenfeld D (1982). Partial residuals for the proportional hazards regression model, Biometrika, 69, 239-241.

상세보기
Surveillance, Epidemiology, and End results (SEER) program (www.seer.cancer.gov) SEER*Stat Database : Incidence - SEER 18 Regs custom data (with additional treatment fields), Nov 2018 Sub (1975-2016 varying) - Linked to county attributes - total US, 1969-2017 counties, national cancer institute, DCCPS, Surveillance research program, released April 2019, based on the November 2018 submission.
Tian L, Zhao L, and Wei LJ (2014). Predicting the Restricted mean event time with the subject's baseline covariates in survival analysis, Biostatistics, 15, 222-233.
Zeger SL and Liang KY (1986). Longitudinal data analysis for discrete and continuous outcomes, Biometrics, 42, 121-130.

상세보기
Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, and Wei LJ (2012). Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study, Clinical Trials, 9, 570-577.

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증